1. Home
  2. ATYR vs HCAT Comparison

ATYR vs HCAT Comparison

Compare ATYR & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • HCAT
  • Stock Information
  • Founded
  • ATYR 2005
  • HCAT 2008
  • Country
  • ATYR United States
  • HCAT United States
  • Employees
  • ATYR N/A
  • HCAT N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • ATYR Health Care
  • HCAT Technology
  • Exchange
  • ATYR Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • ATYR 451.3M
  • HCAT 259.8M
  • IPO Year
  • ATYR 2015
  • HCAT 2019
  • Fundamental
  • Price
  • ATYR $5.31
  • HCAT $4.06
  • Analyst Decision
  • ATYR Strong Buy
  • HCAT Buy
  • Analyst Count
  • ATYR 6
  • HCAT 11
  • Target Price
  • ATYR $20.20
  • HCAT $8.00
  • AVG Volume (30 Days)
  • ATYR 3.5M
  • HCAT 660.7K
  • Earning Date
  • ATYR 08-12-2025
  • HCAT 08-06-2025
  • Dividend Yield
  • ATYR N/A
  • HCAT N/A
  • EPS Growth
  • ATYR N/A
  • HCAT N/A
  • EPS
  • ATYR N/A
  • HCAT N/A
  • Revenue
  • ATYR N/A
  • HCAT $311,274,000.00
  • Revenue This Year
  • ATYR $960.85
  • HCAT $11.23
  • Revenue Next Year
  • ATYR $1,283.47
  • HCAT $9.71
  • P/E Ratio
  • ATYR N/A
  • HCAT N/A
  • Revenue Growth
  • ATYR N/A
  • HCAT 4.88
  • 52 Week Low
  • ATYR $1.48
  • HCAT $3.49
  • 52 Week High
  • ATYR $5.98
  • HCAT $9.24
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 57.23
  • HCAT 57.35
  • Support Level
  • ATYR $4.96
  • HCAT $3.73
  • Resistance Level
  • ATYR $5.47
  • HCAT $4.13
  • Average True Range (ATR)
  • ATYR 0.37
  • HCAT 0.22
  • MACD
  • ATYR -0.07
  • HCAT 0.04
  • Stochastic Oscillator
  • ATYR 61.11
  • HCAT 88.89

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: